Guest Column | November 19, 2026

Unlocking Established Immunological Pathways: How mRNA And LNP Technologies Can Reshape Cancer Therapy

By Salim Dhanji, Ph.D., CEO, ME Therapeutics

data safety, privacy-GettyImages-2285906878

Over the last few decades, immuno-oncology research has identified multiple biological pathways that could be harnessed to activate immune cells, as well as overcome tumor-driven immune suppression and improve the body’s ability to recognize and attack cancer cells. Translating these discoveries into effective and safe therapies, however, has proved challenging, and as a result, patients today still do not benefit from the potential these pathways offer.

One of the main obstacles is understanding how to activate these pathways in a controlled, targeted manner that generates a sufficiently strong response while minimizing unwanted effects. High-profile examples of promising therapeutic approaches that ultimately encountered roadblocks include stimulator of interferon genes (STING) agonists and therapies based on cytokine interleukin-12 (IL-12), both of which generated excitement during early research but went on to demonstrate dose-limiting toxicity in trials.

Recent advances in mRNA and lipid nanoparticle (LNP) technologies provide the immuno-oncology research community with a renewed opportunity to pursue these targets. The latest generation of LNP technologies holds the promise of delivering therapies to precise cells and tissues outside the liver, while mRNA technology allows transient protein expression to be maintained. Our team at ME Therapeutics is applying these advances to revisit one particular biological target: the well-established STING pathway.

The Role Of STING In The Immune System

First identified in 2008, STING is now recognized as a critical mediator of the innate immune system. Operating as a cytosolic DNA sensor, STING helps initiate an immune response when abnormal DNA is detected in a cell, including DNA from certain viruses or damaged tumor cells. When activated, it triggers a signaling cascade that leads to the production of type I interferons and other proinflammatory cytokines. These signals help prime T cells and recruit them into the infected tissue or tumor microenvironment. The result is an antiviral response, or turning “cold” tumors “hot.”

This ability to stimulate an immune response against tumors that otherwise evade immune detection is what has made STING such an attractive target for immuno-oncology. However, as mentioned earlier, the field is still challenged to find a sustained way to activate this pathway that can benefit patients.

Early programs that focused on small molecule STING agonists performed well in preclinical models but faced limitations related to drug delivery, efficacy, and tolerability once they entered the clinic. Given systemically, the agonists often caused excessive, nonspecific immune activation, and with it, dose-limiting toxicities and dangerous cytokine storms. Intratumoral injection was safer but could only be used in accessible tumors, which left metastatic disease largely untreated. Neither approach could target tumors effectively while limiting exposure to healthy tissue. As a result, this established target has yet to demonstrate consistent clinical benefit.

The Promise Of Emerging mRNA And LNP Technologies

The rapid advancement of mRNA and LNP technologies provides a new opportunity to target STING. While earlier generations of LNPs tended to accumulate in the liver, changes to their lipid composition and surface properties are improving delivery precision and efficacy, including the ability to reach cells and tissues outside the liver. This targeted delivery has the potential to improve the therapeutic window.

The technology underpinning engineered mRNA has likewise substantially improved over the last decade, including enhanced stability, greater control over protein expression, and the incorporation of modified nucleosides to reduce unwanted innate immune activation and increase protein production. Since mRNA expression is naturally transient, these technologies also offer a significant advantage over systemic small molecules with reduced risk of sustained, runaway immune toxicity.

At ME Therapeutics, we are applying advances in LNP and mRNA technology to develop an mRNA-based STING therapeutic that can overcome the limitations of earlier approaches, including systemic toxicity and poor tumour targeting, to leverage this well-established pathway for patient benefit.

For delivery, our approach focuses on long-circulating LNP formulations that preferentially accumulate in tumor-associated myeloid cells, which make up a significant portion of the tumor microenvironment in solid cancers. These long-circulating LNPs are optimized to remain in the bloodstream for extended periods before being cleared by the liver, improving the opportunity to deliver cargo to specific tissues and cell targets.

To further reduce protein expression in the liver, we are also making careful modifications to our mRNA sequences to limit how much STING protein is produced in the liver, while preserving expression in other cells. This is important because even with improved LNP formulations, some nanoparticles may still accumulate in liver tissue.

The potential is bearing out in our early results. In vitro testing of our sequence has demonstrated a five-fold reduction in STING protein expression in human hepatocyte cell lines, while expression in nonhepatocyte cells remains preserved and robust.

These findings support the potential for tissue-specific modulation of mRNA expression to drive potent, localized anticancer immune responses while minimizing systemic side effects. Reduced liver activity and enhanced accumulation in the tumor may reduce the dose-limiting systemic toxicity that derailed previous systemic STING agonists, thereby widening the therapeutic window.

This targeted activation of STING could be especially valuable for treating solid tumors with low mutation burdens, such as microsatellite-stable colorectal cancer. However, significant milestones still need to be reached. The next phase of development requires further in vivo preclinical work to establish comprehensive efficacy models, confirm optimal safety profiles, define the ideal dose-response curve, and measure the long-term durability of the STING-mediated immune response.

Broader Implications For The Field

The implications of this application extend beyond STING. Other potent immunological targets, including cytokines (such as IL-12), co-stimulatory molecules, and inflammatory pathways, have previously been deprioritized because they could not be safely confined to the tumor. Now the ability to control where and for how long therapeutic proteins are expressed could open new opportunities to investigate targets previously considered “undruggable” and too difficult or risky to pursue.

Another promising direction is combining mRNA-LNP therapies with existing cancer treatments. By delivering mRNA that encodes proteins capable of triggering complex biological cascades, these therapies could temporarily reprogram cells within the tumor microenvironment to stimulate antitumor immune responses. This could help make previously unresponsive “cold” tumors more susceptible to established treatments, including immune checkpoint inhibitors.

While these possibilities remain to be demonstrated clinically, they represent compelling new lines of inquiry. Progress does not need to rest on discovering new targets. Sometimes, the most profound breakthroughs can come from applying cutting-edge tools to biological targets the field already knows intimately but that were previously too difficult to safely unlock.

About The Author

Salim Dhanji, Ph.D., is the founder and CEO of ME Therapeutics. Dhanji is a former director of preclinical research at Qu Biologics, with industry and academic expertise in cancer, autoimmunity, and inflammation. Prior to his role at Qu Biologics, he was a postdoctoral fellow at the Ontario Cancer Institute where he studied cell signaling pathways involved in autoimmunity and cancer immunity to understand how to manipulate the immune system to achieve an anti-cancer immune response. In addition to his experience in biotechnology, he is the president of perceptive property development and has served in this role since 2013. Dhanji obtained a BS in 2001 and a Ph.D. in microbiology and immunology in 2006, both from UBC.